Author/Authors :
Vukorepa, Gorana Department of Neurology - University Hospital Dubrava - Zagreb, Croatia , Deveđija, Sabina Department of Neurology - University Hospital Dubrava - Zagreb, Croatia , Crnjaković, Miljenko Department of Neurology - University Hospital Dubrava - Zagreb, Croatia , Karakaš, Mirna Department of Neurology - University Hospital Dubrava - Zagreb, Croatia , Ćuk, Željka Department of Neurology - University Hospital Dubrava - Zagreb, Croatia
Abstract :
Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80‑year‑old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 8. Dabigatran was reversed with idarucizumab, and intravenous tissue-type plasminogen activator (IV-tPA) was administrated beginning 4 h and 28 min after the symptom onset. The patient was discharged with an NIHSS of 1. Our case is an additional proof of safety and efficiency of idarucizumab in the clinical setting of ischemic stroke before the administration of IV-tPA.
Keywords :
idarucizumab thrombolysis , anticoagulants dabigatran , acute stroke therapy , Acute ischemic stroke
